Your doctor prescribed Symbicort because your asthma or COPD needs a specific type of treatment, but your insurer denied it. The reason probably has less to do with whether you need an ICS/LABA inhaler (a combination of an inhaled steroid and a long-acting airway opener) than with the fact that your plan's formulary (its preferred drug list) ranks cheaper alternatives ahead of it.

Symbicort (budesonide/formoterol) is the only widely available ICS/LABA that can serve as both your daily controller and your rescue inhaler in a single device. It contains formoterol, an airway opener that works fast enough to also serve as a rescue medication. That fast action is what makes SMART therapy (Single Maintenance and Reliever Therapy) possible. The GINA (Global Initiative for Asthma) 2025 guidelines recommend SMART as the preferred approach for moderate-to-severe asthma. Advair and Breo Ellipta, the alternatives most drug lists prefer, contain airway openers that work more slowly and cannot double as rescue inhalers.

That hasn't stopped insurers from building their drug lists around those alternatives. Most plans prefer generic fluticasone/salmeterol or Breo over Symbicort. Most exclude the brand and only cover the generic version. And plans that do cover it often set a limit on how many inhalers you can get per month, which are frequently too few for SMART therapy patients. The result is that a treatment the guidelines recommend keeps getting blocked by drug lists that weren't designed to support it.

However, denials can be overturned. Fewer than 1% of denied claims are ever appealed, and insurers count on that. But patients who push back with specific evidence see dramatically higher success rates. At Claimable, our appeals succeed over 80% of the time in established conditions.

Symbicort denials look different depending on your diagnosis, your treatment plan, and the specific barrier your insurer put up. A patient denied because the plan caps how many inhalers it will cover each month is in a different situation than one denied because their plan prefers a different inhaler. This guide covers each type and how to respond.

Why Insurance Companies Deny Coverage for Symbicort

The specific denial reason determines your strategy. A patient denied because the plan prefers a different ICS/LABA is in a different situation than one denied because they hit a quantity limit, or one whose plan excluded brand Symbicort in favor of the generic.

What We See Across Thousands of Appeals

These are the most common denial types, what they actually mean, and where to start:

Plan Prefers a Different Inhaler

This is the most common Symbicort denial. Your plan prefers a different ICS/LABA, typically generic fluticasone/salmeterol (generic Advair), Breo Ellipta, or Wixela Inhub, and won't cover Symbicort until you've tried the preferred option.

When the switch makes sense: if your doctor prescribed Symbicort for standard twice-daily maintenance and doesn't plan to use it for SMART therapy, and you don't have a clinical reason to need formoterol specifically, the preferred alternative may work just as well for controlling your asthma or COPD. ICS/LABA inhalers in general are effective at reducing symptoms and exacerbations.

When to appeal: if your doctor prescribed Symbicort specifically for SMART therapy, the preferred alternatives simply cannot fill that role. Advair and Breo contain salmeterol or vilanterol, neither of which work fast enough to be used as a rescue inhaler. Requiring a trial of those alternatives first asks you to fail a medication that cannot perform the function your doctor prescribed Symbicort for. Your appeal should cite the GINA 2025 guidelines, which recommend ICS-formoterol as the preferred treatment approach, and explain the plan's preferred alternatives cannot substitute for Symbicort in SMART therapy. When the block is a straight formulary exclusion rather than a step requirement, a formulary exception request is often the fastest route to coverage.

Other clinical reasons to appeal include: documented intolerance or side effects with the preferred alternative, better symptom control on Symbicort than on the preferred option (if you've already tried it), or a specific clinical feature like exercise-triggered symptoms where formoterol's fast action matters.

Brand Not Covered, Generic Only

Most plans now exclude brand Symbicort and cover only generic budesonide/formoterol or Breyna. This is one of the more straightforward denials.

When to switch: generic budesonide/formoterol contains the same active ingredients at the same doses and meets the same FDA standards proving it works the same way in your body. For most patients, switching to the generic is clinically equivalent and often cheaper.

When to appeal: if you've had a documented adverse reaction to a generic formulation (differences in inactive ingredients or propellant can occasionally cause issues), or if the generic isn't available at your pharmacy. In most cases, though, the generic is usually the simplest option.

Quantity Limit Exceeded

This denial is specific to SMART therapy patients. Standard Symbicort dosing is 2 puffs twice daily (4 puffs per day, 120 puffs per inhaler, roughly a 30-day supply). SMART therapy adds as-needed rescue puffs on top of that maintenance dose, which means patients may need more than one inhaler per month. Most plans set quantity limits at one inhaler per 30 days.

The argument that wins: SMART therapy is the GINA-recommended approach for moderate-to-severe asthma. The additional puffs replace a separate rescue inhaler (typically albuterol), which reduces total medication use and exacerbations over time. Your prescriber should submit a quantity override request with documentation of your asthma severity, the SMART therapy protocol, and the clinical evidence showing that SMART reduces severe exacerbations by roughly 60–65% compared with using only a short-acting rescue inhaler.

Step Therapy Required

Some plans require a trial of a different ICS/LABA before they'll cover Symbicort. This overlaps with the "preferred alternative" denial but is more rigid. Instead of just preferring the alternative, the plan won't approve Symbicort at all until you've tried the required drug and shown it didn't work.

The detail that matters: if the step therapy drug cannot serve the clinical purpose your doctor intended (SMART therapy), requiring you to try it first doesn't make clinical sense. Your appeal should state that the required step therapy drug and budesonide/formoterol are not interchangeable for your prescribed use. Cite the GINA 2025 guidelines and the NHLBI (National Heart, Lung, and Blood Institute) 2020 asthma management guidelines, both of which support SMART therapy with ICS-formoterol specifically. Many states also have step therapy exception protections that require insurers to grant an exception when the required drug is expected to be ineffective for your situation.

Not Medically Necessary

This denial typically means the prior authorization submission didn't include enough clinical detail. A strong resubmission includes your diagnosis with ICD-10 codes (the standard diagnostic codes doctors use) — for example, your asthma severity classification or COPD staging — along with measurable data showing how severe your condition is: spirometry results (a breathing test that measures lung function), exacerbation history, symptom frequency, and current controller medications.

It should also include a clear clinical reason why budesonide/formoterol is the appropriate treatment. For asthma, include your current step level per GINA or NHLBI guidelines. For COPD, include your GOLD classification (the international standard for rating COPD severity) and exacerbation history.

How to Appeal a Symbicort Denial (Step by Step)

Step 0: Verify Your Coding and Benefit Routing

Before you start a formal appeal, confirm that the denial is actually a clinical or formulary decision and not a billing error. Many Symbicort denials trace back to incorrect ICD-10 coding (for example, unspecified asthma instead of moderate persistent asthma), a wrong NDC (the drug's product identification number) or quantity field, or the claim being routed to the wrong benefit (for example, pharmacy instead of medical, or vice versa).

Ask your prescriber's office to verify the diagnosis codes and your pharmacy to confirm the NDC submitted. If the denial letter references a coding or administrative reason, fixing and resubmitting the claim may resolve it without a full appeal.

Step 1: Find Your Deadline

Most commercial plans allow 180 days. UnitedHealthcare limits many plans to 65 calendar days. Medicare Advantage plans allow 60 calendar days. If you miss these windows, you may lose your right to appeal, so mark the deadline as soon as the denial arrives.

Step 2: Use Both Tracks

Your doctor handles the clinical appeal — resubmitting the prior authorization, writing a letter of medical necessity, and requesting a peer-to-peer review (a call where your doctor speaks directly with the insurer's doctor). You file your own patient-initiated appeal on a separate legal track with guaranteed response timelines and the right to external review. These tracks complement each other, and using both gives you the strongest position.

Step 3: Verify Your Documentation

Confirm your diagnosis codes, your disease severity measures (spirometry, exacerbation count, symptom frequency), and treatment history. For SMART therapy appeals specifically, confirm that your prescriber has documented the SMART protocol and the clinical reason for using budesonide/formoterol as both maintenance and rescue.

Step 4: Get a Letter of Medical Necessity

This is an important document in your appeal. It should include your diagnosis with severity classification, treatment history (including any prior ICS/LABA trials and outcomes), and the clinical reason for choosing Symbicort, directly addressing the insurer's denial reason. For SMART therapy appeals, the letter should explain why a formoterol-containing inhaler is clinically necessary and why the plan's preferred alternatives cannot serve the same role.

Ask your doctor directly: "I need a letter of medical necessity for my Symbicort appeal. It should address why I specifically need budesonide/formoterol and why the plan's preferred alternatives won't work for my treatment plan."

Step 5: Build the Appeal Package

A complete appeal includes the cover letter, letter of medical necessity, supporting clinical records (spirometry results, exacerbation history, medication history), and your personal statement. Structure it around three parts: your story (how poorly controlled asthma or COPD affects your daily life, work, sleep, and physical activity), clinical evidence (GINA 2025, NHLBI 2020 guidelines, SMART therapy evidence), and policy and legal analysis (how your case meets the plan's criteria, ACA (Affordable Care Act) protections, and any applicable state laws that let you skip required drug trials when they don't apply to your situation).

Step 6: Submit and Track

Submit per the denial letter instructions. Insurers must respond within 30 days (standard) or 72 hours (urgent). For asthma patients with frequent exacerbations or recent ER visits, an expedited appeal may be appropriate. Keep records of everything.

Step 7: Escalate If Denied Again

You have the right to external review by an independent third party. Their decisions are binding in most states. Additional options include state Department of Insurance complaints, ERISA protections (federal rules that govern employer-sponsored health plans), and state step therapy exception laws.

Appeal Timelines: How Long Does a Symbicort Appeal Take?

Complete submissions move faster. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Symbicort denied when my doctor prescribed it?

Most Symbicort denials are driven by which ICS/LABA your plan prefers, not whether you need one at all. Many drug lists favor generic fluticasone/salmeterol (generic Advair) or Breo Ellipta over budesonide/formoterol, and most now exclude brand Symbicort in favor of the generic version. Your doctor chose budesonide/formoterol for a clinical reason. The insurer is applying its own drug-list preferences on top of that.

Can I appeal a Symbicort denial myself?

Yes. Patient appeals run on a separate legal track from your doctor's clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal. Filing your own appeal complements your doctor's efforts and gives you access to protections and escalation options that the provider track alone does not offer.

Is generic budesonide/formoterol the same as Symbicort?

Yes, in terms of active ingredients, dosing, and FDA standards proving the generic works the same way in your body. Generic budesonide/formoterol (including Breyna) contains the same medications at the same strengths. For most patients, the switch is clinically equivalent. If your plan requires the generic and you don't have a documented reason to stay on brand, switching is usually the fastest path to coverage.

My plan wants me to use Advair or Breo instead. Are they the same?

They're all ICS/LABA combination inhalers, but they're not interchangeable for every use. Advair contains fluticasone/salmeterol. Breo Ellipta contains fluticasone/vilanterol. Neither contains formoterol, which means neither can be used for SMART therapy (using the same inhaler for both maintenance and rescue). If your doctor prescribed Symbicort specifically for SMART, the plan's preferred alternatives cannot serve that clinical purpose.

What is SMART therapy, and why does it affect my coverage?

SMART (Single Maintenance and Reliever Therapy) uses a budesonide/formoterol inhaler for both daily maintenance and as-needed rescue instead of carrying a separate albuterol inhaler. The GINA 2025 guidelines recommend it as the preferred approach for asthma because clinical evidence shows it reduces severe exacerbations by roughly 60–65% compared with using only a short-acting rescue inhaler. SMART affects coverage because it requires more puffs per month than standard maintenance dosing, which can trigger quantity limit denials. It also requires a formoterol-containing inhaler, which conflicts with plans that prefer non-formoterol ICS/LABAs.

How much does Symbicort cost without insurance?

Brand Symbicort runs $350–$500 per inhaler without insurance. Generic budesonide/formoterol costs $150–$300 at retail, or as low as $90–$150 with a discount card. AstraZeneca offers a savings card for brand Symbicort that can cap the cost at $35 per 30-day supply for eligible commercially insured patients. Viatris offers a savings card for Breyna that can reduce the cost to as little as $20 per month for eligible commercially insured patients. For uninsured or underinsured patients who qualify, AstraZeneca's AZ&Me program may provide the medication at no cost.

Is it worth appealing a Symbicort denial?

Yes, especially if the denial is blocking access to SMART therapy or forcing you onto an inhaler that your doctor has already determined isn't appropriate for your situation. Poorly controlled asthma leads to ER visits, hospitalizations, missed work, and gradual loss of lung function. COPD exacerbations carry even more serious consequences. Getting the inhaler your doctor prescribed can mean the difference between controlled disease and a trip to the emergency room. The Schmidtknecht family's story is a stark reminder of what's at stake when asthma medication is delayed. If your doctor prescribed budesonide/formoterol for a clinical reason, an appeal puts that reasoning in front of someone who has to evaluate it.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →